BrainCheck offers BrainCheck Assess™, an FDA Class II digital cognitive assessment suite that lets clinicians in primary care, neurology, and psychiatry rapidly screen and monitor patients for conditions such as mild cognitive impairment and Alzheimer’s disease. The platform produces standardized, repeatable cognitive data and allows providers to customize testing protocols in English or Spanish. Beyond testing, BrainCheck supplies care-planning workflows that have generated more than 14,000 individualized Care Plans and enabled over 640,000 cognitive assessments to date. More than 500 healthcare organizations, including Bon Secours, UPMC and Springfield Clinic, as well as 46 research hospitals like UT Austin and Stanford, currently use the solution. The company is expanding its enterprise cognitive-care infrastructure to support workflow integration, longitudinal monitoring, and population-scale deployment. It also partners with collaborative-care organizations to deliver comprehensive cognitive-care pathways for practices lacking in-house staffing or infrastructure. Future development includes advanced AI-assisted clinical features aimed at risk-bearing and value-based care environments.

Total raised

$52M

Funding rounds

7

Latest round

Series A

Latest activity

Feb 2026